Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma

Additional therapeutic options are needed for relapsed and refractory multiple myeloma (RRMM). We present data from a phase 1b, open-label, dose-escalation study (NCT01965353) of 20 patients with RRMM (median age: 63 years [range: 50–77]) and a median of four prior regimens (range: 2–14); 85% had re...

Descripción completa

Detalles Bibliográficos
Autores principales: Laubach, Jacob P., Tuchman, Sascha A., Rosenblatt, Jacalyn M., Mitsiades, Constantine S., Colson, Kathleen, Masone, Kelly, Warren, Diane, Redd, Robert A., Grayson, Dena, Richardson, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873303/
https://www.ncbi.nlm.nih.gov/pubmed/33563894
http://dx.doi.org/10.1038/s41408-021-00407-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873303/
https://www.ncbi.nlm.nih.gov/pubmed/33563894
http://dx.doi.org/10.1038/s41408-021-00407-5

Ejemplares similares